4 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow John Sampson: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme BTSC mRNA-loaded DCs - Recurrent Central Nervous System Neoplasm | Phase 1 | Completed | John Sampson | 50 | 2009-09-01 | 2016-10-17 |
| Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer CMV-ALT + CMV-DCs, CMV-ALT + Saline - Glioblastoma | Phase 1 | Completed | John Sampson | 23 | 2008-09-01 | 2018-01-30 |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PEP-3 vaccine, sargramostim, Temozolomide - Malignant Neoplasms of Brain | Phase 2 | Completed | John Sampson | 40 | 2007-09-01 | 2017-02-01 |
| Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery PEP-3-KLH conjugate vaccine, daclizumab, temozolomide - Malignant Neoplasms of Brain | Phase 1 | Completed | John Sampson | 16 | 2007-03-01 | 2016-01-21 |
Glioblastoma (4) · Gliosarcoma (3) · Astrocytoma (1) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioma (1)
Temozolomide (2) · Daclizumab (1) · Sodium Chloride (1) · rindopepimut (1) · sargramostim (1)
United States (4)
Gordana Vlahovic, MD (3) · Duane Mitchell, MD, PhD (1)
PMID 18775433, PMID 20921459, PMID 21149254, PMID 22383993
P30CA014236 (1), P50NS020023 (1), R01CA135272 (1), R21CA132891 (1)